Clinical Cancer Research Bridging the Lab and the Clinic in Cancer Medicine Tumor Immunology: New Perspectives
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Parmiani, G.
Right arrow Articles by Santinami, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Parmiani, G.
Right arrow Articles by Santinami, M.
Clinical Cancer Research Vol. 10, 8142-8146, December 15, 2004
© 2004 American Association for Cancer Research

Perspective

Heat Shock Proteins and Their Use as Anticancer Vaccines

Giorgio Parmiani1, Alessandro Testori2, Michele Maio3, Chiara Castelli1, Licia Rivoltini1, Lorenzo Pilla1, Filiberto Belli1, Vincenzo Mazzaferro1, Jorgelina Coppa1, Roberto Patuzzo1, Mario R. Sertoli4, Axel Hoos5, Pramod K. Srivastava6 and Mario Santinami1

1 Istituto Nazionale Tumori and 2 European Institute of Oncology, Milan, Italy; 3 University of Siena, Siena, and 4 Istituto Scientifico Tumori, Genoa, Italy; and 5 Antigenics, Inc., New York, NY; and 6 University of Connecticut, Farmington, Connecticut


   Introduction
Top
 Introduction
Preclinical Characterization of...
 Clinical Trials of Vaccination...
 Other Current Clinical Trials...
 Conclusions
 REFERENCES
 
Despite the improvement in the outcome of anticancer therapy achieved during the last few years, several metastatic tumors remain resistant to therapy. This is particularly true for metastatic melanoma, renal and lung carcinoma, and, although to a lesser extent, for colorectal carcinoma. For these tumors, several biological therapies have been proposed, including vaccination by a variety of approaches. Over the past decade, it has become increasingly apparent that the host immune system can recognize and destroy cancer cells, although this will only rarely translate into a significant clinical benefit (1) . Consequently, antitumor therapies have focused on exploiting the immune response in an attempt to increase its strength and specificity to better control the disease.

Many tumor-associated antigens (TAAs) are now available in the form of single peptide epitopes restricted by known HLA class I or II alleles (see ref. 2 ). However, all of the TAAs used in clinical protocols belonged to the group of normal (i.e., self) peptides/proteins (e.g., gp100, tyrosinase, CEA) shown to be weakly immunogenic in vivo. This may be one important reason for the limited clinical response rate observed in these studies, in addition to mechanisms of immune evasion, which have been reported previously (3) .

Thus, we believe that a new group of TAAs needs to be explored as for purposes of anticancer vaccine development, namely the individual (unique) TAAs that often result from mutations of a variety of proteins. In animal models, these TAAs enable rejection of tumors more potent than that obtained by shared TAAs (4) .

Such individual antigens do exist also in human tumors (see ref. 2 ) and appear to be associated with long-term disease-free condition in the few patients that could be studied (5, 6, 7) . However, with today’s technology, it still requires several months before novel TAAs are identified and characterized for the use in cancer vaccines. In addition, the heterogeneity of human cancers with regard to their molecular background and the resulting antigenic repertoire warrants a polyvalent approach to efficiently address larger numbers of patients within a given disease population. An alternative approach, which carries the promise to circumvent the above challenges, is offered by the use of tumor-derived heat shock protein-peptide complexes (HSPPCs) as cancer vaccines. In fact, Srivastava et al. (8) have shown that tumor-derived autologous heat shock proteins (HSPs) function as chaperones of TAA peptides, and the use of HSPPCs allows for immunization of the host against a large repertoire of individual TAAs. Moreover, mice immunized with heat shock proteins (HSPs) in a therapeutic setting often showed retarded progression of primary cancers and reduced metastatic load (9) . In the following sections, we shall discuss how this principle has been applied for designing new clinical trials of cancer vaccines.


   Preclinical Characterization of HSPs as Cancer Vaccines
Top
 Introduction
 Preclinical Characterization of...
Clinical Trials of Vaccination...
 Other Current Clinical Trials...
 Conclusions
 REFERENCES
 
The molecular chaperones HSP70, Grp94/gp96, calreticulin, and gp110 are well characterized within the family of HSPs. HSP70 has diversified functions, which include chaperoning protein into degradation pathways, binding of new synthesized amino acid chains on ribosomes, and maintaining translocation-competent folding of estrogen receptor and mitochondrial precursor proteins in the cytosol. As for the estrogen receptor resident Grp94/gp96, several authors showed that also this protein displays intrinsic polypeptide-binding activity (see ref. 10 ). Gp110 is related to HSP70 in structure and functions, but it appears more effective in binding and chaperoning full-length proteins (11) .

However, not much is known on the structural requirements for peptide binding to HSPs because the primary sequences of very few peptides directly eluted from HSP70 and gp96 are available (12 , 13) . An important new feature of HSPs is that they bind specifically to antigen-presenting cells through toll-like receptors (TLRs), thus triggering the innate immunity signaling pathways (14 , 15) .

To investigate whether gp96 and HSP70 purified either from human tumors or in vitro cultured melanoma lines could indeed contain TAA peptides, we assessed the ability of tumor-derived gp96 and HSP70 to reconstitute the epitopes recognized by CD8+ T cells specific for melanoma or colorectal carcinoma antigens. For gp96, experiments showed that HLA-A*0201–restricted CD8+ T cells recognizing melanoma (e.g., Melan-A/MART-1) or colorectal carcinoma (CEA and EpCAM) antigens were triggered to release IFN-{gamma} by HLA-A*0201–matched antigen-presenting cells pulsed with HSP96 purified from tumor cells expressing the relevant TAA (16) .

Using a similar approach, we and others showed that also HSP70, purified from a human melanoma line, included peptides from Melan-A/MART-1, gp100, TRP-2, and tyrosinase (17 , 18) . Of note, not only HLA-A*0201 but also HLA-A*0301 and HLA-C*0801–restricted CTLs were specifically triggered by HSP70 derived from the autologous melanoma line 15392, thus indicating that different epitopes were chaperoned by HSP70 deriving from a single tumor (17) .

Unfortunately, because T-cell clones specific for unique class I HLA-restricted melanoma TAAs were not available, the presence of peptides derived from these antigens inside the HSP70 chaperoned peptides could not be assessed, and therefore, the relation of shared versus unique class I HLA-restricted epitopes in human HSP70-chaperoned peptide repertoire is unknown. Altogether, more studies are necessary to prove that unique TAA peptides can bind different members of the HSP families.

Tumor-derived HSPPC-96 appeared to activate TAA-specific T cells and expand them in vivo. In fact, immunization with autologous tumor-derived HSPPC-96 induced a significant increase in the frequency of T lymphocytes recognizing Melan-A/MART-127–35, CEA571–579, and EpCAM263–271 in a subset of HLA-A*0201 melanoma and colorectal carcinoma patients, respectively, as detected by enzyme-linked immunospot and HLA/tetramer staining (16) . These increases in TAA-specific T-cell responses were associated with a favorable disease course after HSPPC-96 vaccination (19 , 20) .

Thus, our data provide evidence that HSPPC-96 derived from human tumors can present TAA peptides to CD8+ T cells and activate them both in vitro and in vivo.

HSPPCs have been shown to display another crucial immunologic function, i.e., the activation of innate immune responses by promoting the maturation of antigen-presenting cells in vitro and in vivo (21 , 22) by binding specific TLRs (22 , 23) . Moreover, a 14-amino acid sequence of HSP70 has been identified that is specifically recognized by human natural killer cells (24) .

This conclusion, however, has been criticized because of the possibility that (a) minute amounts of endotoxins may be responsible for this phenomenon despite the use of different methods aimed at eliminating or reducing such contaminants, or (b) HSPs themselves directly bind bioactive lipids such as lipopolysaccharide and transport it to the antigen-presenting cell receptor (see ref. 25 ). Although it is almost impossible to exclude that undetectable amounts of endotoxins may contaminate or bind HSPs, several findings do not corroborate such an explanation for the antigen-presenting cell activation function of HSPs. In fact, in our ex vivo studies, HSP-96 obtained by the same procedure from histologically different or antigenically unrelated human tumors were used as negative controls, and antigen-presenting cells pulsed with such preparations were not recognized by TAA-specific T-cell clones (16 , 17) . Moreover, recent studies in animal models indicate that HSPs can stimulate in vivo a CD8+ T-cell response through activation of dendritic cells, which is independent of lipopolysaccharide and occurs via the TLR4 (26) . A separation between antigen delivery and dendritic cell stimulation in HSP70 mycobacterial binding domain has also been reported previously (27) .

Thus, although endotoxin contaminants cannot be completely ruled out in the biological activity of HSPs, the role of these contaminants, if any, cannot explain the bulk of the important immunologic functions exerted by these proteins particularly in chaperoning TAA peptides.

Taken together, the above findings, along with the demonstration of anticancer activity of HSPPCs in animal models, provided the rationale for HSPPC-based vaccination in cancer patients.


   Clinical Trials of Vaccination with HSPPC-96 in Metastatic Melanoma and Colorectal Carcinoma Patients
Top
 Introduction
 Preclinical Characterization of...
 Clinical Trials of Vaccination...
Other Current Clinical Trials...
 Conclusions
 REFERENCES
 
The first human clinical study with autologous HSPs was conducted by Janetzki et al. (28) in a small group of miscellaneous tumors. These authors noted signs of clinical responses and found that a T-cell reaction could be generated in a fraction of patients.

Subsequently, a phase II trial was carried out in stage IV (American Joint Committee on Cancer) melanoma patients treated with autologous, tumor-derived HSPPC-96 (Oncophage, Antigenics, Inc., Lexington, MA; ref. 19 ). The trial was designed to investigate safety and immunogenicity and to demonstrate antitumor activity of HSPPC-96 in patients enrolled and treated in four Italian centers. Patients were randomly assigned to receive 5 or 50 µg of HSPPC-96 at weekly intervals starting 5 to 8 weeks after surgical resection of tumor metastases. The study included 45 patients, which were vaccinated, and 39 were considered evaluable for response after having received at least 4 weekly injections of vaccine (one cycle of treatment). Twenty-eight patients had residual measurable disease whereas 11 were disease free after surgery.

Among patients with measurable disease, two complete responses (24 and ≥48 months) and three long-term stable diseases (153, 191, and 272 days) were reported. Disease-free survival of the subgroup of vaccinated patients with no evidence of disease ranged from 29 to 642 days (median, 117 days). No clear correlation between clinical responses and dose of HSPPC-96 could be found; additionally, besides transient erythemas and/or induration at vaccination sites, patients did not experience treatment-related systemic toxicity (19) .

Enzyme-linked immunospot assays showed that vaccination with HSPPC-96 significantly increased the ability of peripheral blood mononuclear cells from 11 of 23 patients tested (47.8%) to release IFN-{gamma} when exposed to autologous or HLA-A–matched melanoma cells. The T-cell involvement in this antitumor reaction was shown by blocking with the anti-HLA class I monoclonal antibody W6/32. These findings indicated that repeated administrations of HSPPC-96 vaccine increased the frequency of melanoma-specific T cells in a large proportion of immunized patients. Noteworthy, the two complete responses and two of the three long-term stable diseases were observed in the group of immunologic responders.

Taken together, the results of this initial study showed that vaccination with HSPPC-96 is feasible, safe, and apparently associated with clinical and immunologic responses in melanoma patients, providing the scientific and clinical rationale for additional trials. An increase of natural killer cell activity in most of the vaccinated patients was also observed, but the role of natural killer cells for the development of clinical responses could not be assessed.

Another phase II study was done by using HSPPC-96 to vaccinate patients after resection of liver metastases of colorectal carcinoma with a schedule similar to that used for melanoma (19) . Patients with colorectal carcinoma who had developed liver metastases after initial treatment of their primary tumors underwent complete surgical resection of their liver disease, and HSPPC-96 was prepared from liver lesions. Four to 6 weeks after surgery, patients were given HSPPC-96. The disease-free and overall survival now at a median follow-up of 48 months in 29 evaluable patients, who received at least four doses of HSPPC-96, were comparable with those reported by our and other groups for similar patients undergoing the same kind of surgery followed by different types of chemotherapeutic regimens. However, a different clinical outcome was reported between the group of subjects showing an increased, class I HLA-restricted T-cell response to colorectal carcinoma cells (n = 17) via the enzyme-linked immunospot assay and those who did not show such a response (n = 12). Immune responders had a statistically significant survival advantage for both disease-free and overall survival at 48 months (Table 1)Citation . Although, because of the limited number of patients, a possible influence of other prognostic factors could not be excluded, these data suggest that HSPPC-96 vaccination not only generated an antitumor immune response in >50% of the subjects but that it may also have contributed to improve patient’s clinical outcome.


View this table:
[in this window]
[in a new window]
  		Table 1 Immune and clinical response in HSPPC-96–vaccinated colorectal carcinoma patients

 

   Other Current Clinical Trials with HSPPCs
Top
 Introduction
 Preclinical Characterization of...
 Clinical Trials of Vaccination...
 Other Current Clinical Trials...
Conclusions
 REFERENCES
 
To date, several other clinical studies have been completed or are ongoing investigating the clinical benefit of autologous cancer-derived HSPPC-96 for patients in either the adjuvant or metastatic disease settings (see ref. 29 ). In fact, there are currently >150 medical centers worldwide enrolling patients in randomized, controlled phase III clinical trials testing this vaccine for the treatment of renal cancer and melanoma. In addition, autologous HSPPCs are being tested in phase I and II trials of chronic myelogenous leukemia, non-Hodgkin’s lymphoma, non–small-cell lung, pancreatic, and gastric cancers (Table 2)Citation .


View this table:
[in this window]
[in a new window]
  		Table 2 Summary of clinical trials testing autologous HSPs in immunotherapy of cancer

 
In an attempt to investigate options to increase the immunogenicity of HSPPC-96, we started a new trial in metastatic melanoma patients (30) by administering HSPPC-96 together with the granulocyte macrophage colony-stimulating factor given at the site of vaccination for 3 subsequent days (–1, 1, +1, 1 being the day of vaccine) and followed by two s.c. injections of 3 x 106 IU of IFN-{alpha}2b to up-regulate the expression of class I HLA often decreased in metastatic melanoma cells (3) . This regimen was given four times weekly, and after 4 weeks of rest, a second cycle of biweekly vaccinations was repeated. The immune response both in terms of frequency and intensity of induction of anti-TAA T cells was not increased as compared with the previous study carried out in similar melanoma patients. Table 3Citation summarizes the anti-melanoma T-cell response, which was found either significantly increased or de novo activated after vaccination with HSPPC-96. With the possible exception of the recent study of HSPPC-96 given with the granulocyte macrophage colony-stimulating factor, the frequency of subjects showing an immune response was reproducible (48 to 52%), a finding of interest if one considers that most of the patients, particularly those with melanoma, had a significant tumor burden.


View this table:
[in this window]
[in a new window]
  		Table 3 Frequency of cancer patients developing de novo or augmenting the HLA class I-restricted antitumor T-cell response after HSPPC-96 vaccination

 
One of the unsolved issues of vaccination is the identification of surrogate markers predictive for clinical response, which may be found in one or more quantitative ex vivo immunologic assays. However, an association between T-cell response and clinical outcome begins to emerge from some of the most recent vaccination trials (19 , 20 , 31 , 32) . In our trials with HSPPC-96, an association was found between class I HLA-restricted antitumor T-cell responses and clinical outcome, although a higher number of clinically responding patients is necessary to corroborate these early findings (19 , 20) .

Safety has been carefully investigated in the studies of vaccination with HSPPCs because of the possibility that self-TAA contained in such preparations could potentially trigger autoimmune reactions. However, no significant laboratory or clinical signs of autoimmunity were reported in the clinical trials done, to date, in >800 patients treated. The safety profile of HSPPC-96 is mostly characterized by mild and transient side effects such as local reactions or low-grade fever. This allows a reasonably good quality of life during treatment.

Limitations of the HSP vaccination approach consist of the requirement of tumor tissue to be removed by surgery and the time necessary for vaccine manufacturing, which may delay or even prevent (in case of disease progression) the treatment. Strategies are being developed at the preclinical and clinical level to solve these problems even with the use of recombinant HSPs and gene manipulation of tumor cells (33 , 34) .


   Conclusions
Top
 Introduction
 Preclinical Characterization of...
 Clinical Trials of Vaccination...
 Other Current Clinical Trials...
 Conclusions
REFERENCES
 
HSPs represent an interesting family of proteins that may function as in vivo chaperones of TAA epitopes carrying peptides, although such conclusion requires additional experimental evidence. However, it appears clear that at least some T-cell epitopes deriving from human TAAs are associated with gp96 and potentially endowed with the ability to stimulate antitumor T cells. The alternative explanation that this may occur through the activation of innate immunity that will then favor the triggering of TAA-specific T cells (35) is difficult to rule out in vivo but can be excluded in most in vitro representation assays with TAA-specific T-cell clones. Thus, at the moment, we conclude that gp96 and HSP70 preparations obtained from human tumors do contain several of the known TAA peptides, which can be recognized by the patients’ immune system.

However, the HSPPC vaccination approach is based on the principle that HSPPCs can potentially bind the full repertoire of the TAAs of a single tumor, including the individual strong antigens that make each tumor antigenically different from the other. By this mechanism, tumor-derived HSPPCs should provide vaccines tailored to the individual patient’s cancer.


   ACKNOWLEDGMENTS
 
We thank the expert technical work of Agata Cova, Gloria Sovena, and Paola Squarcina and the editing assistance of Grazia Barp.


   FOOTNOTES
 
Grant support: Antigenics, Inc. (New York, NY).

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Requests for reprints: Giorgio Parmiani, Unit of Immunotherapy of Human Tumors, Istituto Nazionale Tumori, Via Venezian 1, 20133 Milan, Italy. Phone: 39-0223902328; Fax: 39-0223902630; E-mail: giorgio.parmiani{at}istitutotumori.mi.it

Received 6/29/04; revised 8/27/04; accepted 9/ 2/04.


   REFERENCES
Top
 Introduction
 Preclinical Characterization of...
 Clinical Trials of Vaccination...
 Other Current Clinical Trials...
 Conclusions
 REFERENCES
 

  1. Parmiani G, Castelli C, Dalerba P, et al Cancer immunotherapy with peptide-based vaccines: what have we achieved? Where are we going?. J Natl Cancer Inst (Bethesda) 2002;94:805-18.[Abstract/Free Full Text]
  2. Novellino L, Parmiani G, Castelli C. A listing of human tumor antigens: March 2004 update. Cancer Immunol Immunother 2004;:; Aug 7 [epub ahead of print]
  3. Marincola FM, Jaffe EM, Hicklin DJ, Ferrone S. Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance. Adv Immunol 2000;74:181-273.[Medline]
  4. Dudley ME, Roopenian DC. Loss of a unique tumor antigen by cytotoxic T lymphocyte immunoselection from 3-methylcholanthrene-induced mouse sarcoma reveals secondary unique and shared antigens. J Exp Med 1996;184:441-7.[Abstract/Free Full Text]
  5. Coulie PG, Ikeda H, Baurain JF, Chiari R. Antitumor immunity at work in a melanoma patient. Adv Cancer Res 1999;76:213-42.[Medline]
  6. Karanikas V, Colau D, Baurain JF, et al High frequency of cytolytic T lymphocytes directed against a tumor-specific mutated antigen detectable with HLA tetramers in the blood of a lung carcinoma patient with long survival. Cancer Res 2001;61:3718-24.[Abstract/Free Full Text]
  7. Novellino L, Renkvist N, Rini F, et al Identification of a mutated receptor-like protein tyrosine phosphatase k as a novel, class II HLA-restricted melanoma antigen. J Immunol 2003;170:6363-70.[Abstract/Free Full Text]
  8. Suto R, Srivastava PK. A mechanism for the specific immunogenicity of heat shock protein-chaperoned peptides. Science (Wash. DC) 1995;269:1585-8.[Abstract/Free Full Text]
  9. Tamura Y, Peng P, Liu K, Daou M, Srivastava PK. Immunotherapy of tumors with autologous tumor-derived heat shock protein preparations. Science (Wash. DC) 1997;278:117-20.Erratum in: Science (Wash. DC) 1999;19:283:preceding 1119.[Abstract/Free Full Text]
  10. Srivastava PK. Interaction of heat shock proteins with peptides and antigen presenting cells: chaperoning of the innate and adaptive immune responses. Ann Rev Immunol 2002;20:395-425.[CrossRef][Medline]
  11. Easton DP, Kaneko Y, Subjeck JR. The HSP110 and GRP170 stress proteins: newly recognized relatives of the HSP70s. Cell Stress Chaperones 2000;5:276-90.[CrossRef][Medline]
  12. Nieland TJ, Tan MC, Monne-van Muijen M, Koning F, Kruisbeek AM, van Bleek GM. Isolation of an immunodominant viral peptide that is endogenously bound to the stress protein GP96/GRP94. Proc Natl Acad Sci USA 1996;93:6135-9.[Abstract/Free Full Text]
  13. Ishii T, Udono H, Yamano T, et al Isolation of MHC class I-restricted tumor antigen peptide and its precursors associated with heat shock proteins hsp70, hsp90, and gp96. J Immunol 1999;162:1303-9.[Abstract/Free Full Text]
  14. Asea A, Rehli M, Kabingu E, et al Novel signal transduction pathway utilized by extracellular HSP70: role of toll-like receptor (TLR) 2 and TLR4. J Biol Chem 2002;277:15028-34.[Abstract/Free Full Text]
  15. Vabulas RM, Braedel S, Hilf N, et al The endoplasmic reticulum-resident heat shock protein Gp96 activates dendritic cells via toll-like receptor 2/4 pathway. J Biol Chem 2002;277:20840-53.[Abstract/Free Full Text]
  16. Rivoltini L, Castelli C, Carrabba M, et al Human tumor-derived heat shock protein gp96 mediates in vitro activation and in vivo expansion of melanoma- and colon carcinoma-specific T cells. J Immunol 2003;171:3467-74.[Abstract/Free Full Text]
  17. Castelli C, Ciupitu AM, Rini F, et al Human heat shock protein 70 peptide complexes specifically activate anti-melanoma T cells. Cancer Res 2001;61:222-7.[Abstract/Free Full Text]
  18. Noessner E, Gastpar R, Milani V, et al Tumor-derived heat shock protein 70 peptide complexes are cross-presented by human dendritic cells. J Immunol 2002;169:5424-32.[Abstract/Free Full Text]
  19. Belli F, Testori A, Rivoltini L, et al Vaccination of metastatic melanoma patients with autologous tumor-derived heat shock protein gp96-peptide complexes: clinical and immunologic findings. J Clin Oncol 2002;20:4169-80.[Abstract/Free Full Text]
  20. Mazzaferro V, Coppa J, Carabba M, et al Vaccination with autologous tumor-derived heat-shock protein gp96 after liver resection for metastatic colorectal cancer. Clin Cancer Res 2003;9:3235-45.[Abstract/Free Full Text]
  21. Binder RJ, Anderson KM, Basu S, Srivastava PK. Cutting edge: heat shock protein gp96 induces maturation and migration of CD11c+ cells in vivo. J Immunol 2000;165:6029-35.[Abstract/Free Full Text]
  22. Singh-Jasuja H, Scherer HU, Hilf N, et al The heat shock protein gp96 induces maturation of dendritic cells and down-regulation of its receptor. Eur J Immunol 2000;30:2211-5.[Medline]
  23. Basu S, Binder RJ, Srivastava PK. CD91 is a common receptor for heat shock proteins gp96, hsp90, hsp70, and calreticulin. Immunity 2001;14:303-13.[CrossRef][Medline]
  24. Gastpar R, Gross C, Rossbacher L, Ellwart J, Riegger J, Multhoff G. The cell surface-localized heat shock protein 70 epitope TKD induces migration and cytolytic activity selectively in human NK cells. J Immunol 2004;172:972-80.[Abstract/Free Full Text]
  25. Wallin RPA, Lundqvist A, Morè SH, von Bonin A, Kiessling R, Ljunggren H-G. Heat-shock proteins as activators of the innate immune system. Trends Immunol 2002;23:130-5.[CrossRef][Medline]
  26. Palliser D, Huang Q, Hacohen N, et al A role of toll-like receptor 4 in dendritic cell activation and cytolytic CD8+ T cell differentiation in response to a recombinant heat shock fusion protein. J Immunol 2004;172:2885-93.[Abstract/Free Full Text]
  27. MacAry PA, Javid B, Andres Floto R, et al HSP70 peptide binding mutants separate antigen delivery from dendritic cell stimulation. Immunity 2004;20:95-106.[CrossRef][Medline]
  28. Janetzki S, Palla D, Rosenhauer V, Lochs H, Lewis JJ, Srivastava PK. Immunization of cancer patients with autologous cancer derived heat shock protein gp96 preparations: a pilot study. Int J Cancer 2000;88:232-8.[CrossRef][Medline]
  29. Hoos A, Levey DL. Vaccination with heat shock protein-peptide complexes: from basic-science to clinical applications. Expert Rev Vaccines 2003;2:369-79.[CrossRef][Medline]
  30. Parmiani G, Pilla L, Pennacchioli E, et al Phase II study of HSPPC-96 in combination with GM-CSF and IFN-alpha in stage IV malignant melanoma. Proc Am Soc Clin Oncol Annu Meet 2004;709:
  31. Bancherau J, Palucka AK, Dhodapkar M, et al Immune and clinical responses in patients with metastatic melanoma to CD34+ progenitor-derived dendritic cell vaccine. Cancer Res 2001;61:6451-8.[Abstract/Free Full Text]
  32. Kirkwood JM, Lee S, Land S, et al E1696: final analysis of the clinical and immunological results of a multicenter ECOG phase II trial of multi-epitope peptide vaccination for stage IV melanoma with MART-1(27-35), gp100(209-217, 210M), and tyrosinase (368-376, 370D) (MGT) ± IFN-alpha2b and GM-CSF. Proc Am Soc Clin Oncol Annu Meet 2004;707:
  33. Massa C, Guiducci C, Arioli I, Parenza M, Colombo MP, Melani C. Enhanced efficacy of tumor cell vaccines transfected with secretable hsp70. Cancer Res 2004;64:1502-8.[Abstract/Free Full Text]
  34. Manjili MH, Henderson R, Wang X-Y, Chen X, et al Development of a recombinant HSP110-HER-2/neu vaccine using the chaperoning properties of HSP110. Cancer Res 2002;62:1737-42.[Abstract/Free Full Text]
  35. Nicchitta CV. Re-evaluating the role of heat-shock protein-peptide interactions in tumour immunity. Nat Rev Immunol 2003;3:427-32.[CrossRef][Medline]



This article has been cited by other articles:


Home page
 J. Immunol.Home page
S. Koido, E. Hara, S. Homma, M. Mitsunaga, A. Takahara, E. Nagasaki, H. Kawahara, M. Watanabe, Y. Toyama, S. Yanagisawa, et al.
Synergistic Induction of Antigen-Specific CTL by Fusions of TLR-Stimulated Dendritic Cells and Heat-Stressed Tumor Cells
J. Immunol., October 1, 2007; 179(7): 4874 - 4883.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
Y. Enomoto, A. Bharti, A. A. Khaleque, B. Song, C. Liu, V. Apostolopoulos, P.-x. Xing, S. K. Calderwood, and J. Gong
Enhanced Immunogenicity of Heat Shock Protein 70 Peptide Complexes from Dendritic Cell-Tumor Fusion Cells
J. Immunol., November 1, 2006; 177(9): 5946 - 5955.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. Sensi and A. Anichini
Unique Tumor Antigens: Evidence for Immune Control of Genome Integrity and Immunogenic Targets for T Cell-Mediated Patient-Specific Immunotherapy
Clin. Cancer Res., September 1, 2006; 12(17): 5023 - 5032.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Parmiani, G.
Right arrow Articles by Santinami, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Parmiani, G.
Right arrow Articles by Santinami, M.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online